Payment overview · 2025
General Payments
$442.44
29 reported records · 6 companies
Healthcare provider profile · identity verified
William White, APRN
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · DYERSBURG, TN · NPI 1902578669
Verified facts
What the public records show
CMS Open Payments records show William White, APRN received $442.44 in general payments during 2025 across 29 reported records.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) accounted for 41.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Symbicort by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $184.96 | 41.8% | 11 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $148.66 | 33.6% | 14 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $35.98 | 8.1% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $29.04 | 6.6% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $24.78 | 5.6% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $19.02 | 4.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $442.44 | 29 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $184.96 | 11 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $148.66 | 14 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $43.80 | 2 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $35.98 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $29.04 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 36 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
55 | 22 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
36 | 15 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
47 | 20 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
21 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 859 | 218 |
| Gabapentin | Gabapentin | 558 | 158 |
| Atorvastatin Calcium | Atorvastatin Calcium | 512 | 223 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 406 | 153 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 312 | 115 |
| Furosemide | Furosemide | 307 | 119 |
| Amlodipine Besylate | Amlodipine Besylate | 296 | 122 |
| Famotidine | Famotidine | 280 | 105 |
| Montelukast Sodium | Montelukast Sodium | 252 | 97 |
| Omeprazole | Omeprazole | 250 | 98 |
| Pantoprazole Sodium | Pantoprazole Sodium | 249 | 95 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 247 | 63 |
| Tizanidine Hcl | Tizanidine Hcl | 232 | 90 |
| Trazodone Hcl | Trazodone Hcl | 232 | 82 |
| Lisinopril | Lisinopril | 210 | 84 |
| Metformin Hcl | Metformin Hcl | 210 | 77 |
| Levothyroxine Sodium | Levothyroxine Sodium | 194 | 71 |
| Fluticasone Propionate | Fluticasone Propionate | 193 | 87 |
| Buspirone Hcl | Buspirone Hcl | 192 | 70 |
| Losartan Potassium | Losartan Potassium | 190 | 74 |
| Potassium Chloride | Potassium Chloride | 175 | 74 |
| Alendronate Sodium | Alendronate Sodium | 173 | 59 |
| Sertraline Hcl | Sertraline Hcl | 153 | 65 |
| Metoprolol Tartrate | Metoprolol Tartrate | 133 | 50 |
| Duloxetine Hcl | Duloxetine Hcl | 131 | 54 |
| Eliquis | Apixaban | 114 | 46 |
| Carvedilol | Carvedilol | 107 | 48 |
| Tamsulosin Hcl | Tamsulosin Hcl | 107 | 47 |
| Clopidogrel | Clopidogrel Bisulfate | 106 | 40 |
| Glimepiride | Glimepiride | 105 | 42 |
| Baclofen | Baclofen | 102 | 34 |
| Hydrochlorothiazide | Hydrochlorothiazide | 102 | 40 |
| Januvia | Sitagliptin Phosphate | 101 | 29 |
| Doxepin Hcl | Doxepin Hcl | 100 | 37 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 92 | 43 |
| Prednisone | Prednisone | 91 | 68 |
| Quetiapine Fumarate | Quetiapine Fumarate | 90 | 26 |
| Allopurinol | Allopurinol | 86 | 39 |
| Meloxicam | Meloxicam | 86 | 35 |
| Ropinirole Hcl | Ropinirole Hcl | 86 | 31 |
| Metoprolol Succinate | Metoprolol Succinate | 84 | 36 |
| Ezetimibe | Ezetimibe | 78 | 40 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 77 | 68 |
| Diclofenac Sodium | Diclofenac Sodium | 75 | 41 |
| Citalopram Hbr | Citalopram Hydrobromide | 74 | 27 |
| Amoxicillin | Amoxicillin | 73 | 71 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 70 | 32 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 70 | 20 |
| Topiramate | Topiramate | 69 | 27 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 67 | 21 |
| Celecoxib | Celecoxib | 66 | 33 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 65 | 26 |
| Meclizine Hcl | Meclizine Hcl | 65 | 33 |
| Ondansetron Hcl | Ondansetron Hcl | 65 | 28 |
| Aripiprazole | Aripiprazole | 64 | 20 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 62 | 21 |
| Promethazine Hcl | Promethazine Hcl | 61 | 30 |
| Amitriptyline Hcl | Amitriptyline Hcl | 58 | 22 |
| Clonidine Hcl | Clonidine Hcl | 56 | 26 |
| Hydralazine Hcl | Hydralazine Hcl | 56 | 24 |
| Jardiance | Empagliflozin | 56 | 14 |
| Spironolactone | Spironolactone | 56 | 24 |
| Tramadol Hcl | Tramadol Hcl | 56 | 13 |
| Doxycycline Hyclate | Doxycycline Hyclate | 55 | 44 |
| Linzess | Linaclotide | 55 | 22 |
| Ozempic | Semaglutide | 55 | 18 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 53 | 23 |
| Pregabalin | Pregabalin | 53 | 16 |
| Bupropion Xl | Bupropion Hcl | 51 | 19 |
| Enalapril Maleate | Enalapril Maleate | 51 | 24 |
| Escitalopram Oxalate | Escitalopram Oxalate | 51 | 18 |
| Oxcarbazepine | Oxcarbazepine | 51 | 16 |
| Solifenacin Succinate | Solifenacin Succinate | 48 | 16 |
| Farxiga | Dapagliflozin Propanediol | 47 | 20 |
| Lamotrigine | Lamotrigine | 46 | 22 |
| Donepezil Hcl | Donepezil Hcl | 45 | 17 |
| Cephalexin | Cephalexin | 44 | 40 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 44 | 20 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 43 | suppressed |
| Ibuprofen | Ibuprofen | 43 | 17 |
| Metformin Hcl Er | Metformin Hcl | 43 | 24 |
| Fenofibrate | Fenofibrate Nanocrystallized | 42 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 42 | suppressed |
| Levetiracetam | Levetiracetam | 40 | 14 |
| Acarbose | Acarbose | 39 | 17 |
| Fluoxetine Hcl | Fluoxetine Hcl | 39 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 37 | 14 |
| Clonazepam | Clonazepam | 36 | 14 |
| Vraylar | Cariprazine Hcl | 36 | 15 |
| Mirtazapine | Mirtazapine | 34 | 11 |
| Valsartan | Valsartan | 34 | 14 |
| Pravastatin Sodium | Pravastatin Sodium | 32 | 12 |
| Propranolol Hcl | Propranolol Hcl | 32 | 17 |
| Risperidone | Risperidone | 32 | suppressed |
| Methocarbamol | Methocarbamol | 31 | 16 |
| Methylprednisolone | Methylprednisolone | 31 | 27 |
| Novolog Mix 70-30 | Insulin Aspart Prot/Insuln Asp | 31 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 31 | 12 |
| Bupropion Hcl Sr | Bupropion Hcl | 30 | 17 |
| Nifedipine Er | Nifedipine | 30 | 15 |
| Dexlansoprazole Dr | Dexlansoprazole | 29 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 28 | suppressed |
| Xarelto | Rivaroxaban | 28 | suppressed |
| Mupirocin | Mupirocin | 27 | 21 |
| Azithromycin | Azithromycin | 26 | 24 |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 26 | suppressed |
| Methotrexate | Methotrexate Sodium | 26 | suppressed |
| Ondansetron Odt | Ondansetron | 26 | 19 |
| Warfarin Sodium | Warfarin Sodium | 26 | 12 |
| Zolpidem Tartrate | Zolpidem Tartrate | 26 | 12 |
| Fluconazole | Fluconazole | 25 | 23 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 25 | suppressed |
| Synthroid | Levothyroxine Sodium | 25 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 25 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 24 | suppressed |
| Alprazolam | Alprazolam | 23 | suppressed |
| Atenolol | Atenolol | 23 | 13 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 22 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 21 | 12 |
| Symbicort | Budesonide/Formoterol Fumarate | 21 | 13 |
| Prazosin Hcl | Prazosin Hcl | 20 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 20 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 19 | suppressed |
| Fenofibrate | Fenofibrate | 19 | suppressed |
| Lubiprostone | Lubiprostone | 19 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 19 | suppressed |
| Acyclovir | Acyclovir | 18 | suppressed |
| Lactulose | Lactulose | 18 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 18 | suppressed |
| Nystatin | Nystatin | 18 | 17 |
| Raloxifene Hcl | Raloxifene Hcl | 18 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 17 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 17 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 17 | suppressed |
| Novolog Flexpen | Insulin Aspart | 17 | suppressed |
| Olanzapine | Olanzapine | 17 | suppressed |
| Simvastatin | Simvastatin | 17 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 17 | 14 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 17 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 16 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 16 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 16 | suppressed |
| Lorazepam | Lorazepam | 15 | suppressed |
| Sucralfate | Sucralfate | 15 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 14 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 14 | suppressed |
| Memantine Hcl | Memantine Hcl | 14 | suppressed |
| Primidone | Primidone | 14 | suppressed |
| Sotalol | Sotalol Hcl | 14 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 14 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 13 | suppressed |
| Cilostazol | Cilostazol | 13 | suppressed |
| Lovastatin | Lovastatin | 13 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Febuxostat | Febuxostat | 12 | suppressed |
| Finasteride | Finasteride | 12 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Diazepam | Diazepam | 11 | suppressed |
| Movantik | Naloxegol Oxalate | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | 11 |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $442.44 · 29 records | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | BREZTRI, CAPLYTA, FANAPT, REXULTI, VRAYLAR | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Vraylar play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error